Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Development stage||Note|
|02/12/19||GEM063||Novel 24hr ibuprofen patch||Local pain in sprains||Local||Phase 1 completed||High payload: Contains 200 mg ibuprofen, Constant delivery over 24 hours, Class-leading adhesion, Water-resistant, Comfortable to wear and remove
Pre-clinical safety studies were completed 2017 with no concerns/issues
Phase I PK and sensitisation/irritancy studies were successfully completed in 2018 with no concerns/issues
|01/11/19||GEM009||BET inhibitor||Cancer, RA||Oral||Preclinical||Updated on January 11, 2019
More potent enzyme inhibition and anti-tumor activities compared with competitors (more potent than GSK525762A and comparble to ABBV-075).
Superior safety profile than competitors (no inhibition on hERG or CYP3A4) and can be applied to RA.
Easier manufacturing due to absence of asymmetric carbon.
|01/11/19||GEM003||Selective glucocorticoid receptor agonist||RA/OA, Please refer to Note||Local||Preclinical||Updated on January 11, 2019
Expected to reduce unfavorable responses of glucocorticoids by selectivity of action (transrepression>transactivation)
Discontinued development for RA/OA. Available for repositioning.
Possible indications: Atopic dermatitis, Psoriasis, Asthma, COPD, Inflammatory bowel disease etc.
|01/11/19||GEM002||Kappa-opioid receptor agonist||Pain/Itching, Please refer to Note||Oral||Preclinical||Updated on January 11, 2019
Discontinued development for pain because of company strategy. Available for repositioning.
Possible indications: Chronic pains (Back pain, Arthritis pain, Cancer pain, Post-herpetic neuralgia, Trigeminal neuralgia etc), Pruritus, Irritable bowel syndrome
|01/11/19||GEM001||TRPV-1 agonist||Rheumatoid Arthritis, Please refer to Note||Oral||Phase 2a||Updated on January 11, 2019
Potently inhibits TNF-a production by oral administration.
Discontinued development for RA. Available for repositioning.
Possible indications: Neuropathic pain, Crohn’s disease, Systemic lupus erythematosus, Cachexia, Acute infectious disease, Allergy, Pyrexia, Anemia, Diabetes, Diseases related TNF-α (Colitis, Psoriasis ets.)
|01/07/19||GEM062||Cannabinoid-releasing topical formulation (siustained release for about 24 hours)||Chronic pain, Sclerosis, Lupus, others||Topical||Preclinical||Cannabinoid’s utility: nausea and vomiting during chemotherapy, chronic pain, muscle spasms, epilepsy, sclerosis, lupus, schizophrenia etc.
This sustained-release topical formulation has significant potential to help treat these disorders. Preclinical efficacy demonstrated in a cutaneous lupus rodent model using AEA.
|01/07/19||GEM061||Curcumin-releasing topical formulation (sustained release for about 24 hours)||Please refer to Note||Topical||Preclinical||Indication:
Osteoarthritis, CV disease, chronic inflammatory disease, vascular disease (Sickle Cell)
Curcumin’s utility: chronic pain, chronic inflammatory conditions such as osteoarthritis, vascular disease such as Sickle Cell and diabetes.
This formulation breaks through the limitations of the poor bioavailability of curcumin with oral administration. Preclinical efficacy demonstrated in an rodent arthritis model and a rodent diabetes model.
|01/07/19||GEM060||Nitric Oxide-releasing topical formulation (sustained release for over 48 hours)||Please refer to Note||Topical||Preclinical||Indication:
Acne, Atopic Dermatitis, Fungal diseases, Wound healing, Chronic rhinosinusitis, Diabetic foot ulcers, Raynaud’s Phenomenon, Middle-ear infections, Erectile dysfunction, Others
NO function: Regulation of the vasculature (vasodilatory), broad spectrum antimicrobial activity, anti-inflammatory, anti-oxidant, wound healing, skin cell maturation and survival etc.
Human POC already shown with NO in onychomycosis, genital warts, moscullum contagiosum, pulmonary hypertension, acne, atopic dermatits (preliminary); animal POC demonstrated in over 20 peer-reviewed papers.
This formulation breaks through the limitations of sustained NO (topical) delivery.
|12/27/18||GEM059||Recombinant Human Interleukin-1 Receptor Antagonist||Please refer to Note||IM||Phase 1||Indication:
1: Infection, as manifested by febrile neutropenia, in patients with malignancies receiving chemotherapy drugs.
2: Diarrhea in patients with malignancies receiving chemotherapy drugs.
3. Gout arthritis
The world's first multiorgan protection agent for tumor chemotherapy.
Inhibits cell cycle progression of normal cells and renders them resistanace to chemotherapy.
No effects on tumor growth and their sensitivity to chemotherapy
Phase 1 : No dose limiting toxicity, None of subjects presented grade 3 or above chemotherapy-induced neutropenia or diarrhea.
Gout arthritis: Well tolerated and safe for patients who are restricted from NSAID, glucocorticoid, or colchicine.
|12/27/18||GEM058||Increase cellular ATP and promote wound healing||Diabetes foot ulcer||Topical||Phase 2||Reducing inflammation of endothelial cells of blood vessels.
Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. The arrangement of actin which is essential for cell migration is ATP dependent.
Applicable to all kind of wound and low cost treatment
Phase 2: The estimated complete closure rate is around 60% (vs placebo 30%)